新一代疫苗 2679条(本栏目收费,不能显示细节,电话13136136841)
probability of success scoring vaccines for,21,22 22
protocol development components of,29 29
vaccines that can be transmitted personto-person onsiderations for,30 30
recombinant DNA technology,12,15 15
regulatory considerations in international trials,29 29
regulatory issues investigational new drugs application components of,27 27
[Vaccine candidate clinical evaluation of new]selection process,25 25
Diarrheal diseases,570,831 831
Dihydroepiandosterone (DHEA),543 543
Dihydrofolate reductase-thymidylate synthase (DHFR-TS) L. major knockout,794 794
4-(4;6-Dimethoxy[1;3;5]triazin-2-yl)-4-methyl-morpholinium,222 222
Diphtheria-tetanus-pertussis (DPT),465 465
Diphtheria toxoid-conjugated meningococcal ACYW CV vaccine,444 444
Disability-adjusted life years (DALYs),105 105
Good clinical practice (GCP),27,28,117,125 125
Good manufacturing practices (GMP),147 147
environmental conditions,148 148
equipment used in,149 149
pharmaceutical water,149 149
basic components,147,148 148
population-based surveillance,467 467
immunization regimens impact of in England and Wales,454,455 455
in Netherlands,455,456 456
in Republic of Ireland,455 455